OncoMatch/Clinical Trials/NCT06973564
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Is NCT06973564 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including JAB-23E73 and JAB-23E73 for advanced solid tumors.
Treatment: JAB-23E73 · JAB-23E73 · JAB-23E73 — This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS alteration
Patients must have KRAS alterations.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS G12C inhibitor
Patients who have previously been treated with KRAS G12C inhibitors
Cannot have received: KRAS G12D inhibitor
Patients who have previously been treated with KRAS G12D inhibitors
Cannot have received: pan/multi-KRAS inhibitor
Patients who have previously been treated with ... pan/multi-KRAS inhibitors
Lab requirements
Cardiac function
lvef ≤50% assessed by echo or muga [excluded]; qt interval>470 msec [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
- Washington University · St Louis, Missouri
- Cleveland Clinic Foundation · Cleveland, Ohio
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify